生命科学资讯
生物技术与制药领域的最新动态
Illumina: Q4 Earnings Snapshot - kens5.com
Illumina shares tumble as flat revenue disappoints investors By Investing.com - Investing.com
Illumina Inc. Q4 Profit Advances - Nasdaq
Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myers’ waiting game
Novo's threat to sue Hims over Wegovy pill faces legal hurdle
Illumina (NASDAQ:ILMN) Reports Bullish Q4 CY2025 - TradingView
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 - PR Newswire
White House plans to launch TrumpRx Thursday
安斯泰来业绩超预期，Vyloy销售激增盖过试验挫折
Astellas tops expectations as Vyloy sales surge outshines trial setback
拜耳与BMS和强生竞争，其药物asundexian显示可降低26%中风风险，为获FDA批准铺平道路。
Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA
量子加密技术或成打造“防黑客”互联网的关键
A hack-proof internet? Quantum encryption could be the key
Veradermics首席执行官喜迎IPO首日股价飙升122%
Veradermics CEO has a great hair day with 122% pop in IPO
诺和诺德与礼来股价受挫，Hims推出仿制GLP-1减肥药。
Novo, Lilly sputter as Hims launches knockoff GLP-1 pill
#ISC26：拜耳asundexian在III期试验中将缺血性中风风险降低26%
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial
拜耳详述新型抗凝血药物预期中风预防数据
Bayer details anticipated stroke prevention data for new blood-thinner